PRO-PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE9 (PCSK9) VARIANT DATABASE: PRELIMINARY ANALYSIS
✍ Scribed by S.E. Leigh; T. Jakubcova; R.A. Whittall; S.E. Humphries
- Book ID
- 118422784
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 54 KB
- Volume
- 207
- Category
- Article
- ISSN
- 0021-9150
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) induces degradation of low‐density lipoprotein receptor (LDLR) in the liver. It is being pursued as a therapeutic target for LDL‐cholesterol reduction. Earlier genome‐wide gene expression studies showed that PCSK9 over‐expression in
## Abstract LDL cholesterol (LDL‐C) is cleared from plasma via cellular uptake and internalization processes that are largely mediated by the low‐density lipoprotein cholesterol receptor (LDL‐R). LDL‐R is targeted for lysosomal degradation by association with proprotein convertase subtilisin‐kexin